TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02717871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PACK-CXL
Description: Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~* 3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~* Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~* Homatropin or Scopolamin, if anterior chamber reaction~* Systemic NSAID/NSAR, if substantial pain~* Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin in combination with either tobramycin or gentamicin
Description: Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cycloplegic agents (cyclopentolate 1% eye drops)
Description: Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )
Description: Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
Study: NCT03244592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matched placebo
Study: NCT02717871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)
Description: Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
Study: NCT01511627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia + Spinal anesthesia combined
Description: All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~* Bupivacaine 0.5% 10 mg~* Fentanyl 10ug~* Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (control group)
Description: All patients will receive a preoperative multimodal analgesic regime:~* Tylenol® 975mg per os~* Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~* Midazolam 1 - 2 mg intravenously~* Fentanyl 1 - 2 ug/kg intravenously~* Propofol 1-3 mg/kg intravenously~* Rocuronium 0.3 - 0.9mg/kg intravenously~* followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~* Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~* Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~* Dexamethasone 4mg and Ondansetron 4mg intravenously~* Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU).
Study: NCT01866475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-IO
Description: To have an EZ-IO placed up to 48 hours
Study: NCT03957096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD47M
Description: SGN-CD47M administered intravenously
Study: NCT00668395

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Description: The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Description: The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).

Intervention type: DRUG
Group type: OTHER
Intervention: Efavirenz
Description: The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
Study: NCT02285049

Intervention type: OTHER
Intervention: Urticaria Control Test
Description: * The patients get the 1st UAS28 form and four-week appointment to follow up.~* Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~* Then patients fill the 1st UCT and DLQI questionnaire by themselves.~* The patients get the 2nd UAS28 form and four-week appointment to follow up.~* At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves.
Study: NCT04459754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu Formulation
Description: The prescription for colorectal cancer Fuzheng Yiliu formulation is a combination of 13 herbal components and it is available in granules form to be dissolved in hot water for consumption.
Study: NCT01866475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-IO
Description: To have an EZ-IO placed up to 48 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-IO
Description: To have an EZ-IO placed up to 48 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EZ-IO
Description: To have an EZ-IO placed up to 48 hours
Study: NCT03114995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Study: NCT02522520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer intervention
Description: 12 weeks physical activity intervention (supervised/non-supervised)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer + hospital based intervention
Description: 12 weeks physical activity intervention (supervised/non-supervised)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omron Walking Style pro. 20

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omron Walking Style pro. 20
Study: NCT01755286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single intra-operative injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-201
Description: Single intra-operative injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Simulated single intratympanic injection
Study: NCT02182882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GINSANA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01039090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Apomorphine infusion
Description: Continuous Apomorphine infusion during 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual dopaminergic per os treatment
Description: No specific change in the dopaminergic per os treatment
Study: NCT04896905

Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitative procedures in isolation ward

Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitative procedures in isolation ward

Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitative procedures in isolation ward
Study: NCT03040219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Tablets
Study: NCT01697761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
Study: NCT00855192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindful meditation
Description: interpersonal and psycho-educational

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interpersonal therapy
Description: psycho-educational
Study: NCT01093261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Fludrocortisone
Description: HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
Study: NCT01036087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
Study: NCT02089451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
Study: NCT04364945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: administration of dexmedetomidine 1 mcg/kg/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: administration of remifentanil 0.1-0.2 mcg/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia is maintained using sevoflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia is maintained using sevoflurane.
Study: NCT02708641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg IV given every three weeks
Study: NCT04376983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation for patients with a cardiac resynchronisation device
Description: Using the device-measured physical activity to create tailored motivational messages and tips to the patients to increase physical activity
Study: NCT02580682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfu herbal patch
Description: The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfu moxibustion
Description: Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sanfu herbal patch and moxibustion
Description: use Sanfu moxibustion followed by Sanfu herbal patch
Study: NCT03826563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral melatonin tablets (NatureMade brand)
Description: melatonin tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill placebo
Study: NCT01530399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 1
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 2
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
Study: NCT03098927

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motor imagery training
Description: Motor imagery training
Study: NCT01530399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 3
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDCO 4
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
Study: NCT03476018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-100
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-100
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-100
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
Study: NCT03067896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
Study: NCT03844412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream
Description: Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream
Description: Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
Study: NCT03637127

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask
Study: NCT04211480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γ-globin reactivated autologous hematopoietic stem cells
Description: gene edited autologous hematopoietic stem cells with γ-globin expression
Study: NCT00766493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® Embolic Filter
Description: Embolic protection during carotid stenting
Study: NCT03844412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
Study: NCT05337969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Vildagliptin 850/50 mg
Description: 50 mg Vildagliptin + 850 mg Metformin as single-dose per study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Vildagliptin 850/50 mg
Description: 50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
Study: NCT02403674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine
Description: One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRIPLA™
Description: One ATRIPLA™ tablet taken q.d. by mouth

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
Study: NCT03844412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream
Description: The comparison treatment will be an identical-appearing placebo Moisturel™ cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: The comparison treatment will be an identical-appearing placebo Moisturel™ cream
Study: NCT01551589

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Field Irradiation(IFI)
Description: Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33\~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33\~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33\~35F，once a day, 5 times per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
Study: NCT03067896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
Study: NCT01439529

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Device programming: nominal
Description: CRT device is programmed to nominal values

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programming optimization by QRS
Description: CRT device is programmed by QRS optimization